(Last updated: July 14, 2016; last reviewed: July 14, 2016)
Revisions to the January 28, 2016, version of the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents include key updates to several sections. Significant updates are highlighted throughout the document.
Key Updates
What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient
The approval of 3 fixed-dose combination products containing tenofovir alafenamide (an oral prodrug of tenofovir) and emtricitabine (TAF/FTC) prompted several changes in the What to Start section. The key changes are highlighted below:
Hepatitis B Virus (HBV)/HIV Coinfection
Hepatitis C Virus (HCV)/HIV Coinfection
Tuberculosis (TB)/HIV Coinfection
Additional Updates
Minor revisions were made to the following sections: